Ishikawa Y, Sorota S, Kiuchi K, Shannon R P, Komamura K, Katsushika S, Vatner D E, Vatner S F, Homcy C J
Department of Pharmacology, College of Physicians and Surgeons of Columbia University, New York 10032.
J Clin Invest. 1994 May;93(5):2224-9. doi: 10.1172/JCI117219.
We have shown that the heart expresses two distinct forms of adenylylcyclase mRNA, types V and VI. In this study we have characterized the expression of these two mRNA species in heart failure generated by overdrive pacing at a rate of 240 beats/min. After 4 wk, left ventricular end-diastolic pressure and heart rate increased significantly with the appearance of signs of heart failure, i.e., edema, ascites, and exercise intolerance. Basal as well as forskolin-stimulated adenylylcyclase activities decreased significantly, which was accompanied by a reduction in the steady state mRNA levels of adenylylcyclase types V and VI. These data suggest that in this model of cardiomyopathy, the downregulation of adenylylcyclase catalytic activity results, at least in part, from a reduction in the steady state levels of types V and VI adenylylcyclase mRNA levels.
我们已表明心脏表达两种不同形式的腺苷酸环化酶mRNA,即V型和VI型。在本研究中,我们对以240次/分钟的超速起搏产生的心力衰竭模型中这两种mRNA种类的表达进行了表征。4周后,左心室舒张末期压力和心率显著增加,并出现心力衰竭的体征,即水肿、腹水和运动不耐受。基础以及福斯高林刺激的腺苷酸环化酶活性显著降低,同时伴有腺苷酸环化酶V型和VI型稳态mRNA水平的降低。这些数据表明,在这种心肌病模型中,腺苷酸环化酶催化活性的下调至少部分是由于V型和VI型腺苷酸环化酶mRNA稳态水平的降低所致。